Graybug Vision, Inc. (NASDAQ:GRAY – Get Free Report) shares dropped 2.8% during trading on Friday . The stock traded as low as $3.95 and last traded at $4.03. Approximately 4,748 shares changed hands during trading, an increase of 119% from the average daily volume of 2,165 shares. The stock had previously closed at $4.14.
Graybug Vision Price Performance
The business’s 50-day moving average is $4.32 and its two-hundred day moving average is $4.65. The firm has a market cap of $6.32 million, a P/E ratio of -0.17 and a beta of 1.20.
Graybug Vision Company Profile
Graybug Vision, Inc, a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.
Further Reading
- Five stocks we like better than Graybug Vision
- How to Calculate Stock Profit
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Pros And Cons Of Monthly Dividend Stocks
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is the Australian Securities Exchange (ASX)
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.
